missing translation for 'onlineSavingsMsg'
Learn More
Learn More
CA19-9/Sialyl Lewisa (GI Tumor Marker) Ab-1 Mouse Monoclonal Antibody, Epredia™
Tous les produits Epredia ProduitsDescription
Mucin glycoprotein is a sialyl Lewisa structure which is synthesized from type 1 blood group precursor chains and is present in individuals expressing the Lewisa and/or Lewisb blood group antigens. In normal tissues, sialyl Lewisa antigen is present in ductal epithelium of the breast, kidney, salivary gland, and sweat glands. Its expression is greatly enhanced in serum as well as in the majority of tumor cells in gastrointestinal (GI) carcinomas, including adenocarcinomas of the stomach, intestine, and pancreas. Preoperative elevated CA19-9 levels in patients with stage I pancreatic carcinoma decrease to normal values following surgery. When used serially, CA19-9 can predict recurrence of disease prior to radiographic or clinical findings.
Host Species: Mouse
Clone: 121SLE
Isotype: IgM
Species Reactivity: Human. Does not react with rat. Others not tested.
Immunogen: Mucins from ovarian cyst
Molecular Weight: >400kDa
Positive Control: Colon CA
Cellular Localization: Cytoplasmic
Recommended for:
- Immunohistochemistry (Formalin/paraffin)
Spécification
Spécification
| Antigène | CA19-9/Sialyl Lewissuperscriptasuperscript (GI Tumor Marker) Ab-1 |
| Applications | Immunohistochemistry (Paraffin) |
| Classification | Monoclonal |
| Clone | 121SLE |
| Concentration | 200μg/mL |
| Conjugué | Unconjugated |
| Espèces hôtes | Mouse |
| Immunogène | Mucins from ovarian cyst |
| Quantité | 500 μL |
| État réglementaire | IVD |
| Afficher plus |
Nom du produit
En cliquant sur Soumettre, vous reconnaissez que vous pouvez être contacté par Fisher Scientific au sujet des informations que vous avez fournies dans ce formulaire. Nous ne partagerons pas vos informations à d'autres fins. Toutes les informations de contact fournies seront également conservées conformément à notre politique de confidentialité. Politique de confidentialité.
Vous avez repéré une opportunité d'amélioration ?